期刊文献+

肝内胆管癌中ErbB4的表达及临床意义 被引量:7

ErbB4 expression in intrahepatic cholangiocarcinoma and its clinical significance
原文传递
导出
摘要 目的:探讨表皮生长因子受体Erb B4在人肝内胆管癌(ICC)组织中的表达及意义。方法:采用免疫组化法分别检测24例ICC患者癌组织(ICC组)、癌旁胆管组织(癌旁组)及16例肝内胆管结石患者胆管组织(结石组)中Erb B4的表达,并分析Erb B4表达与ICC患者临床病理因素的关系。结果:Erb B4的强阳性表达率在ICC组中为75.0%,明显高于癌旁组(45.8%)和结石组(37.5%)(均P<0.05);且ICC组胞核Erb B4阳性表达率高于另两组(均P<0.05),而胞膜与胞质Erb B4阳性表达率3组间差异无统计学意义(均P>0.05)。Erb B4的高表达与ICC患者淋巴结转移及TNM分期有关(均P<0.05)。结论:Erb B4的表达增高与核内移与ICC的发生发展以及浸润转移密切相关。 Objective: To investigate the expression of epidermal growth factor receptor Erb B4 in human intrahepatic cholangiocarcinoma(ICC) tissues and its significance. Methods: The ErbB 4 expressions in 24 paired specimens of ICC tissue(ICC group) and adjacent bile duct tissue(tumor adjacent group), and 16 specimens of bile duct tissue from hepatolithiasis patients(hepatolithiasis group) were detected by immunohistochemical staining, and the relations of ErbB 4 expression with the clinicopathologic factors of ICC patients were also analyzed.Results: The strong positive expression rate of ErbB 4 in ICC group was 75.0%, which was significantly higher than that in tumor adjacent group(45.8%) or hepatolithiasis group(37.5%)(both P〈0.05), nuclear expression rate of ErbB 4 in ICC group was significantly higher than that in the other two groups(both P〈0.05), while the membranous and cytoplasmic expression rates of ErbB 4 showed no significant difference among the three groups(both P〉0.05). High ErbB 4 expression was significantly associated with lymph node metastasis and TNM stage of ICC patients(both P〈0.05).Conclusion: Increased expression of Erb B4 and its transfer into cellular nucleus are closely related to the occurrence and development as well as infiltration and metastasis of ICC.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2015年第2期180-184,共5页 China Journal of General Surgery
基金 湖南省医药卫生科研计划资助项目(B2013-071) 湖南省科学技术厅科技计划资助项目(2014FJ3033)
关键词 胆管肿瘤 胆管 肝内 受体 表皮生长因子 肿瘤侵润 Bile Duct Neoplasms Bile Ducts Intrahepatic Receptor Epidermal Growth Factor Neoplasm Invasiveness
  • 相关文献

参考文献20

  • 1Lepage C, Cottet V, Chauvenet M, et al. Trends in the incidence and management of biliary tract cancer: a French population-based study[J]. J Hepatol, 2011, 54(2):306-310.
  • 2吕品,蒋波,王俊,刘剑鸣,谭永辉.PROX-1与Ki-67在胆管癌中的表达及意义[J].中国普通外科杂志,2014,23(8):1082-1086. 被引量:6
  • 3周少君,黄志勇.肝内胆管癌根治性切除术后肿瘤复发转移的预后因素分析[J].中国普通外科杂志,2014,23(8):1024-1029. 被引量:22
  • 4Sarah B.Fisher,Kevin E.Fisher,Shishir K.Maithel,冯铁成(编译),李新营(编译).分子靶向治疗胆道恶性肿瘤:靶点的确定[J].中国普通外科杂志,2013,22(8):971-972. 被引量:1
  • 5Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics[J]. Curt Opin Cell Biol, 2007, 19(2): 124-134.
  • 6Schulze WX, Deng L, Mann M. Phosphotyrosine interactome of the ErbB-receptor kinase family[J]. Mol Syst Biol, 2005, 1:2005.
  • 7Burgess AW. EGFR family: structure physiology signalling and therapeutic targets[J]. Growth Factors, 2008, 26(5):263-274.
  • 8Chang JL, Tsao YP, Liu DW, et al. The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix[J]. J Biomed Sci, 2001, 8(2):206-213.
  • 9Starr A, Greif J, Vexler A, et al. ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy[J]. Int J Cancer, 2006, 119(2):269- 274.
  • 10逄旭光,范虹,葛棣.HER4基因抑制对食管癌细胞Eca-109迁移和侵袭能力的影响[J].复旦学报(医学版),2008,35(4):521-527. 被引量:6

二级参考文献51

  • 1Takehiro Okabayashi,Yasuo Shima,Tatsuaki Sumiyoshi,Akihito Kozuki,Satoshi Ito,Yasuhiro Ogawa,Michiya Kobayashi,Kazuhiro Hanazaki.Diagnosis and management of insulinoma[J].World Journal of Gastroenterology,2013,19(6):829-837. 被引量:85
  • 2葛棣,冯明祥,曾亮.表皮生长因子受体家族在食管癌中表达的临床研究[J].中国临床医学,2004,11(5):717-720. 被引量:11
  • 3吴孟超,吴在德.黄家驷外科学[M].第7版.北京:人民卫生出版社,2008:1340-1341.
  • 4Parkin DM, Bray FIoDevesa SS. Cancer burden in the year 2000. The global picture[J].Eur J Cancer. 2001,37 ( Suppl 8):S4-S66.
  • 5Enzinger PC, Mayer RJ. Esophageal cancer[J]. N Engl J Med,2003.349:2 241 -2 252.
  • 6Normanno N,Bianco C, Strizzi L,et al. The ErbB receptors and their ligands in cancer: an overview[J].Curr Drug Targets, 2005,6 : 243 - 257.
  • 7Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration drug approval summary:gefitinib (ZD1839: Iressa): tablets[J].Clin Cancer Res, 2004,10:1 212-1 218.
  • 8Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trialof gefitinib for previously treated patients with advanced non-small cell lung cancer[J].J Clin Oncol,2003,21:2 237-2 246.
  • 9Graber HU, Friess H, Kaufmann B, et al. ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer[J].Int J Callcer, 1999,84:24- 27
  • 10Lee JC, Wang ST, Chow NH, et al. Investigation of the prognostic value of co-expressed erbB family members for the survival of colorectal cancer patients after curative surgery[J].Eur J Cancer.2002,38:1 065-1 071.

共引文献31

同被引文献39

  • 1沈新生,王燕蓉.氧化苦参碱对CCl4所致小鼠肝损伤修复作用的形态学研究[J].解剖科学进展,1997,0(3):57-58. 被引量:22
  • 2Patel T. Cholangiocarcinoma-controversies and challenges[J]. Nat Rev Gastroenterol Hepatol, 2011, 8(4):189-200.
  • 3Patel T. Worldwide trends in morality from biliary tract malignancies[J]. BMC Cancer, 2002, 2:10.
  • 4Aljiffry M, Abdulelah A, Walsh M, et al. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature[J]. J Am Coll Surg, 2009, 208(1):134-147.
  • 5Sharma R, Gibbs JF. Recent advances in the management of primary hepatic tumours refinement of surgical techniques and effect on outcome[J]. J Surg Oncol. 2010, 101(8):745-754.
  • 6Mavros MN, Economopoulos KP, Alexiou VG, et al. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis[J]. JAMA Surg, 2014, doi: 10.1001/jamasurg.2013.5137.
  • 7Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy[J]. Hepatology, 2005, 41(1):5-15.
  • 8Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment[J]. Hepatology, 2008, 48(1):308-321.
  • 9Arnold D, Peinert S, Voigt W, et al. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review[J]. Oncologist, 2006, 11(6):602-611.
  • 10Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2012, 13(2):181-188.

引证文献7

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部